| Overall | Indonesia | Kyrgyzstan | Nigeria | |
---|---|---|---|---|---|
n (%) | n (%) | n (%) | n (%) | ||
Implementation of BPaL as the SoC for treatment of XDR-TB and MDR-TB treatment failure/intolerance based on initial profile (Nix) | Total | 166 | 46 | 50 | 70 |
Likely | 146 (88%) | 40 (87%) | 43 (86%) | 63 (90%) | |
Neutral | 18 (11%) | 6 (13%) | 7 (14%) | 5 (7%) | |
Unlikely | 2 (1%) | 0 (0%) | 0 (0%) | 2 (3%) | |
Implementation of BPaL as SoC for treatment of Fq resistant TB without additional resistance to 2nd line injectables based on initial profile (Nix) | Total | 169 | 46 | 55 | 68 |
Likely | 142 (84%) | 38 (83%) | 44 (80%) | 60 (88%) | |
Neutral | 20 (12%) | 8 (17%) | 10 (18%) | 2 (3%) | |
Unlikely | 7 (4%) | 0 (0%) | 1 (2%) | 6 (9%) |